Related Experiment Video

Updated: Jun 29, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis

P Valentino1, A Labate, R Nisticò

  • 1Institute of Neurology, University Magna Graecia, Catanzaro, Italy.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 11, 2008
PubMed
Abstract

Insights

In relapsing-remitting multiple sclerosis (RRMS), elevated anti-GM1 antibodies were found in 37.8% of patients. However, these antibodies did not correlate with brain atrophy, suggesting they are not a marker for axonal damage.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Biochemistry

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
  • Axonal damage is a key contributor to long-term disability in MS.
  • Anti-GM1 antibodies have been investigated as potential biomarkers in neurological disorders.

Purpose of the Study:

  • To investigate the correlation between brain atrophy and serum anti-GM1 antibody levels in RRMS patients.
  • To determine if anti-GM1 antibodies serve as a marker for axonal damage in RRMS.

Main Methods:

  • Plasma samples from 52 RRMS patients and 65 healthy controls were analyzed for anti-GM1 antibodies.
  • Brain imaging using the SIENAX automated method was performed on RRMS patients to estimate gray matter (GM(V)) and white matter (WM(V)) volumes.

Main Results:

  • 37.8% of RRMS patients exhibited increased levels of anti-GM1 antibodies.
  • No significant correlation was found between elevated anti-GM1 antibody levels and brain atrophy (GM(V) or WM(V)) in RRMS patients.

Conclusions:

  • Anti-GM1 antibodies do not appear to be a reliable marker of axonal damage in patients with RRMS.
  • Further research is needed to identify specific biomarkers for axonal damage in MS.

More Related Videos

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...